Senior Associate Scientist, Transgenic Biology
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Sr. Associate Scientist to join our Velocigene Assisted Reproductive Technology and Transgenic Biology group, expanding our in vitro and in vivo gene editing capabilities. In this hybrid molecular biology, cell culture, and in vivo role, you will run CRISPR experiments (Cas9, prime editing, and base editing), build sequencing and long-read libraries, and support mouse studies from injection through tissue collection, driving innovation in genome modification techniques and tools for therapeutic advancements.
Job description
Discover your role
- Perform cell culture-based experiments, including transfection, electroporation, and viral transduction across immortalized cell lines and primary cells
- Design and execute CRISPR/Cas9 experiments, including guide design, delivery, and downstream analysis of editing outcomes
- Perform molecular biology techniques, including PCR, qPCR, cloning, and nucleic acid/protein handling
- Prepare DNA for sequencing applications, including long-read and ONT library prep where applicable
- Manage in vivo mouse studies, including tail vein and retro-orbital injections, tissue dissection, and sample collection
- Work independently to plan, execute, and troubleshoot experiments under the supervision of colleagues and manager
- Collaborate closely with team members and cross-functional partners
- Maintain thorough, timely records and summarize/present results in formal and informal settings
This role requires
- M.S. preferred, with 2-5 years of directly relevant hands-on laboratory experience
- Hands-on experience with cell culture technique, including transfection, electroporation, and viral transduction
- Prior hands-on experience working with mice
- Strong bench skills with a demonstrated ability to work independently and troubleshoot experiments
- A genuine eagerness to learn new techniques and a strong collaborative mindset
- Preferred: experience with CRISPR/Cas9-based genome editing
- Preferred: experience with Western Blot, ELISA, FACS, and flow cytometry (panel design and analysis)
- Preferred: experience with injections (IP, tail vein, and/or RO) and tissue collection, and long-read/ONT sequencing workflows
Requirements
- M.S. preferred, with 2-5 years of directly relevant hands-on laboratory experience
- Hands-on experience with cell culture technique, including transfection, electroporation, and viral transduction
- Prior hands-on experience working with mice
- Strong bench skills with a demonstrated ability to work independently and troubleshoot experiments
- A genuine eagerness to learn new techniques and a strong collaborative mindset
- Preferred: experience with CRISPR/Cas9-based genome editing
- Preferred: experience with Western Blot, ELISA, FACS, and flow cytometry (panel design and analysis)
- Preferred: experience with injections (IP, tail vein, and/or RO) and tissue collection, and long-read/ONT sequencing workflows
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.